-
招银国际-Diversified and highly-differentiated pipeline-210902
2021-09-02
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:4 页
-
招银国际-泰格医药-300347-Strong backlog growth driven by solid demand-210827
2021-08-27
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:4 页
-
招银国际-信达生物-01801.HK-Building world-leading innovation platform-210827
2021-08-27
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:4 页
-
招银国际-药明生物-02269.HK-Earnings beat driven by strong demand in COVID-19 related projects-210825
2021-08-25
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:4 页
-
招银国际-药明康德-603259-Strong recovery continued-210816
2021-08-16
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:4 页
-
招银国际-开拓药业-B-09939.HK-Encouraging real-world data of proxalutamide in COVID-19 treatment in Paraguay-
2021-07-26
作者:Sam HU,Jill Wu,Jonathan Zhao
评级:
页数:6 页
-
招银国际-信达生物-01801.HK-Growing into a global biopharma company-210722
2021-07-22
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:77 页
-
招银国际-亚盛医药-B-06855.HK-Encouraging results of APG-2575 and APG-115 released at 2021 ASCO Annual Meetin
2021-06-10
作者:Sam HU,Jill Wu,Jonathan Zhao
评级:
页数:6 页
-
招银国际-亚盛医药-B-06855.HK-Encouraging results of APG-2575 and APG-115 released at 2021 ASCO Annual Meetin
2021-06-10
作者:Sam HU,Jill Wu,Jonathan Zhao
评级:
页数:6 页
-
招银国际-亚盛医药-B-06855.HK-Encouraging results of APG-2575 and APG-115 released at 2021 ASCO Annual Meetin
2021-06-10
作者:Sam HU,Jill Wu,Jonathan Zhao
评级:
页数:6 页
-
招银国际-Uliledlimab disclosed promising data from the US phase I study-210521
2021-05-21
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:5 页
-
招银国际-药明康德-603259-Stronger-than-expected growth in Q1-210430
2021-05-06
作者:Jill Wu,Sam HU,Jonathan Zhao
评级:
页数:4 页
-
招银国际-药明康德-603259-Building cutting-edge expertise to secure longterm growth-210401
2021-04-01
作者:Jill Wu,Sam HU
评级:
页数:6 页
-
招银国际-Multiple important clinical readouts in 2021-210331
2021-03-31
作者:Jill Wu,Sam HU
评级:
页数:5 页
-
招银国际-诺诚健华-B-09969.HK-Entering into commercial stage-210329
2021-03-29
作者:Sam HU,Jill Wu
评级:
页数:5 页
-
招银国际-开拓药业-B-09939.HK-Fast clinical progress for Proxalutamide and other core assets-210329
2021-03-29
作者:Sam HU,Jill Wu
评级:
页数:5 页
-
招银国际-石药集团-01093.HK-Multiple innovative drugs to receive approvals in 2021-210316
2021-03-16
作者:Jill Wu,Sam HU
评级:
页数:4 页
-
招银国际-先声药业-02096.HK-FDA approved trilaciclib for chemotherapy-induced myelosuppression-210301
2021-03-01
作者:Sam HU,Jill Wu
评级:
页数:4 页
-
招银国际-开拓药业-B-09939.HK-Enrollment completed for proxalutamide for hospitalized COVID-19 patients in Br
2021-02-26
作者:Sam HU,Jill Wu
评级:
页数:5 页
-
招银国际-平安好医生-01833.HK-Emphasis on its core online medical service capabilities-210204
2021-02-05
作者:Jill Wu,Sam HU
评级:
页数:5 页
-
招银国际-Expect rich R&D catalysts-210201
2021-02-02
作者:Jill Wu,Sam HU
评级:
页数:11 页
-
招银国际-泰格医药-300347-Better business recovery outlook in 2021E-210129
2021-01-29
作者:Jill Wu,Sam HU
评级:
页数:4 页
-
招银国际-平安好医生-01833.HK-Endeavor to upgrade channels and services-210126
2021-01-26
作者:Jill Wu,Sam HU
评级:
页数:5 页
-
招银国际-药明康德-603259-Strong growth outlook in 2021 and beyond-210125
2021-01-25
作者:Jill Wu,Sam HU
评级:
页数:5 页
-
招银国际-德琪医药-B-06996.HK-Leading Asia-Pacific biopharmaceutical company developing first-in-class SINE c
2021-01-08
作者:Sam HU,Jill Wu
评级:
页数:79 页